Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Analysts at Leerink Partnrs lifted their Q4 2025 EPS estimates for Travere Therapeutics in a research note issued to investors on Friday, October 11th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings per share of $0.30 for the quarter, up from their previous forecast of $0.25. The consensus estimate for Travere Therapeutics' current full-year earnings is ($3.95) per share.
Other equities research analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. lifted their price objective on shares of Travere Therapeutics from $20.00 to $23.00 and gave the company an "overweight" rating in a research report on Friday, September 13th. Guggenheim raised their price target on Travere Therapeutics from $23.00 to $41.00 and gave the stock a "buy" rating in a research report on Wednesday, October 9th. HC Wainwright cut their price objective on Travere Therapeutics from $23.00 to $18.00 and set a "buy" rating on the stock in a research report on Friday, September 27th. Leerink Partners reaffirmed an "outperform" rating and set a $20.00 target price on shares of Travere Therapeutics in a research report on Tuesday, October 8th. Finally, Wedbush increased their target price on shares of Travere Therapeutics from $17.00 to $25.00 and gave the stock an "outperform" rating in a report on Wednesday, October 9th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, Travere Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $19.75.
Check Out Our Latest Report on TVTX
NASDAQ TVTX opened at $16.41 on Monday. Travere Therapeutics has a 52 week low of $5.12 and a 52 week high of $18.60. The stock's 50-day moving average price is $11.78 and its 200-day moving average price is $8.98. The company has a quick ratio of 2.99, a current ratio of 3.04 and a debt-to-equity ratio of 24.96.
Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.03). The company had revenue of $54.12 million for the quarter, compared to analysts' expectations of $49.50 million. Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 269.18%.
In related news, CEO Eric M. Dube sold 21,125 shares of Travere Therapeutics stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.52, for a total transaction of $243,360.00. Following the completion of the transaction, the chief executive officer now directly owns 361,975 shares in the company, valued at approximately $4,169,952. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Christopher R. Cline sold 2,490 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.52, for a total transaction of $28,684.80. Following the sale, the chief financial officer now directly owns 74,595 shares of the company's stock, valued at $859,334.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Eric M. Dube sold 21,125 shares of the firm's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.52, for a total value of $243,360.00. Following the sale, the chief executive officer now owns 361,975 shares in the company, valued at $4,169,952. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 110,707 shares of company stock valued at $1,504,312 in the last quarter. 3.75% of the stock is currently owned by company insiders.
A number of hedge funds have recently bought and sold shares of the business. Assenagon Asset Management S.A. lifted its position in shares of Travere Therapeutics by 912.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 2,214,099 shares of the company's stock valued at $18,200,000 after buying an additional 1,995,419 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of Travere Therapeutics by 79.2% in the first quarter. Russell Investments Group Ltd. now owns 184,623 shares of the company's stock valued at $1,423,000 after purchasing an additional 81,611 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Travere Therapeutics during the first quarter worth about $452,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Travere Therapeutics during the 4th quarter worth about $5,711,000. Finally, Acadian Asset Management LLC lifted its stake in Travere Therapeutics by 202.6% in the 2nd quarter. Acadian Asset Management LLC now owns 144,901 shares of the company's stock valued at $1,190,000 after buying an additional 97,020 shares in the last quarter.
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Travere Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.
While Travere Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.